| scholarly article | Q13442814 |
| P50 | author | Suhnggwon Kim | Q85792610 |
| Jeffrey R Curtis | Q87706464 | ||
| Jun Won Park | Q89468182 | ||
| P2093 | author name string | Eun Bong Lee | |
| Yeong Wook Song | |||
| Jinyoung Moon | |||
| P2860 | cites work | Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients | Q24193204 |
| Current epidemiology of Pneumocystis pneumonia | Q28289603 | ||
| Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states | Q34033833 | ||
| Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome | Q34577534 | ||
| When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases | Q34788682 | ||
| Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology | Q35551818 | ||
| Pneumocystis pneumonia | Q35800451 | ||
| Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients | Q35920640 | ||
| Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials | Q36931056 | ||
| Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients | Q38196066 | ||
| Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid | Q38364778 | ||
| Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. | Q40705059 | ||
| Adverse drug reactions: definitions, diagnosis, and management | Q40739350 | ||
| Pneumocystis jirovecci pneumonia in connective tissue diseases: Comparison with other immunocompromised patients | Q41362507 | ||
| Quantification of the effect of chemotherapy and steroids on risk of Pneumocystis jiroveci among hospitalized patients with adult T-cell leukaemia. | Q41722330 | ||
| Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment | Q42231929 | ||
| Pneumocystis pneumonia in solid organ transplantation | Q42272280 | ||
| Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus | Q46337694 | ||
| A survey of rheumatologists' practice for prescribing pneumocystis prophylaxis | Q46556046 | ||
| A solution to the problem of separation in logistic regression. | Q52942642 | ||
| An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. | Q54394711 | ||
| Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy | Q70828301 | ||
| Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy | Q79211608 | ||
| Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004 | Q80497353 | ||
| Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients | Q82430801 | ||
| Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases | Q85016620 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pneumonia | Q12192 |
| rheumatism | Q684924 | ||
| P304 | page(s) | 644-649 | |
| P577 | publication date | 2017-11-01 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids | |
| P478 | volume | 77 |
| Q92919169 | Antibiotic treatment and flares of rheumatoid arthritis: a self-controlled case series study analysis using CPRD GOLD |
| Q92464818 | Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation |
| Q90338391 | Emergent high fatality lung disease in systemic juvenile arthritis |
| Q96155644 | Epidemiology of Pneumocystis jirovecii Pneumonia and (Non-)use of Prophylaxis |
| Q89635103 | Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study |
| Q89497679 | Inflammatory Myopathy-Related Interstitial Lung Disease: From Pathophysiology to Treatment |
| Q95592748 | Lupus nephritis |
| Q92106591 | Niflumic Acid Reverses Airway Mucus Excess and Improves Survival in the Rat Model of Steroid-Induced Pneumocystis Pneumonia |
| Q90415655 | Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review |
| Q89533562 | Pneumocystis jirovecii Pneumonia and Other Infections in Idiopathic Inflammatory Myositis |
| Q90525356 | Pneumocystis jirovecii colonization and its association with pulmonary diseases: a multicenter study based on a modified loop-mediated isothermal amplification assay |
| Q90107170 | Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole |
| Q93374087 | Therapy and Management of Pneumocystis jirovecii Infection |
| Q88687918 | Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review |
| Q89293824 | Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis |
Search more.